In this paper, we review some of the research findings including (i) clinical trials on the efficacy of LiveSpo® Navax delivered through nasal spray in the treatment and prevention of ARTIs in children infected with RSV and influenza, and (ii) two case studies on the efficacy of LiveSpo® Navax in the treatment of symptomatic Covid-19 infection in two families of individuals with moderate and mild symptoms.